Trials / Completed
CompletedNCT04002895
What the Body Does to Foliglurax in Healthy Volunteers
Interventional, Open-label, Single-dose Study Investigating the Absorption, Metabolism and Excretion (AME) of Foliglurax (Lu AF99757) Following Oral Dosing of 14C-foliglurax to Healthy Men
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- Male
- Age
- 45 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This study evaluates how the body takes up and gets rid of foliglurax after swallowing a liquid dose.
Detailed description
Six healthy men will swallow a liquid dose of 80 mg that is labelled with a small dose of radioactive tracer. Blood, urine and faeces will be collected to measure how much of the radioactivity gets into the blood stream and ends up in the urine and faeces. It is also measured how the body gets rid of the radioactivity and how quickly.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Foliglurax | Single oral dose of 80 mg \[14C\]-foliglurax(93µCi/3.44 MBq), 1mg/mL oral solution (prepared from \[14C\]-foliglurax powder for oral solution) |
Timeline
- Start date
- 2019-06-27
- Primary completion
- 2019-08-01
- Completion
- 2019-08-08
- First posted
- 2019-07-01
- Last updated
- 2019-11-04
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04002895. Inclusion in this directory is not an endorsement.